CRAMSN is a One-Stop-Shop CRO, CMO and CDMO service partner for the pharmaceutical industry. We differentiate ourselves with the world class R&D and manufacturing capabilities enabling partners to transform their Ideas from Concept to commercial. CRAMSN’s ability to offer end-to-end solutions or support standalone programs with efficiency, quality, and consistency enables faster go-to-market strategies and improved access for patients while placing sustainability and social responsibility at the core of our ambitions.

CRAMSN Research Park is a state-of-the-art facility designed to support a wide range of chemical and pharmaceutical production activities, from small-scale synthesis to large-scale manufacturing for clinical trials and commercialization. The CRAMSN Research Park has a comprehensive set of reactors, with capabilities ranging from 5L to 100L in scale for synthesis and data generation, as well as larger 5KL reactors for kilo lab-scale production. The facility is capable of synthesizing both cGMP and non-GMP materials for clinical studies (from grams to kilograms), and is equipped for addressing complex pharmaceutical needs, such as stability studies, polymorphism analysis, and solid-state characteristics.

Key features include:

Scalability: From small-quantity production (grams) to large-scale operations (tons), enabling flexible production for different stages of development.
Advanced Chemical Expertise: Specialized in various chemical transformations including asymmetric catalysis, chiral resolutions, halogenations, oxidation, reduction, and enzymatic processes.
Cryogenic & HPAPI Capabilities: The facility can handle extreme temperatures (-90°C to 140°C) and highly potent APIs with strict safety measures.
Specialized Equipment: Including hydrogenation reactors, spray dryers, particle size reduction, and peptide synthesis reactors (SPPS & LPPS). It also features advanced purification tools like ATEX prep HPLC systems and lyophilization units.
Quality and Safety: The facility emphasizes safety with features, HPAPI containment, and a Class 100,000 cleanroom for particle size reduction.For finished dosage forms (FDF), CRAMSN Research Park excels in a wide range of formats:

Solid Dosage Forms: Tablets (~12 billion), capsules (~2 billion), granules (~100 tons), and multi-layered, sustained, and controlled release formulations.
Oral Liquids: Including syrups, solutions, and suspensions (~7 million).
Parenteral: Injectable formulations, including ampoules, vials, depot injections, and pre-filled syringes (~40 million units).

Additionally, CRAMSN has dedicated blocks for oncology products, positioning itself as a specialist in cancer treatment manufacturing. The versatility and cutting-edge technologies available make it a highly capable partner for pharmaceutical production across various stages and product types.